Pfizer-Seagen innovation theory of harm would be difficult for FTC to prove in court
Pfizer and Seagen have said antitrust regulators have a lot of questions about whether innovation will be maintained after their deal. But while the companies didn’t indicate which jurisdiction is focused...To view the full article, register now.
Already a subscriber? Click here to view full article